{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:05:19Z","timestamp":1792098319725,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T00:00:00Z","timestamp":1482883200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Keyaki-kai grant from the Graduate School of Medical Science, Kitasato University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s12185-016-2173-1","type":"journal-article","created":{"date-parts":[[2016,12,28]],"date-time":"2016-12-28T09:26:30Z","timestamp":1482917190000},"page":"614-622","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["CD109, a negative regulator of TGF-\u03b2 signaling, is a putative risk marker in diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"105","author":[{"given":"Maki","family":"Yokoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Ichinoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sosei","family":"Okina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutaka","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Nakada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Yanagisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Xu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Numata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Umezawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Higashihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Murakumo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,28]]},"reference":[{"key":"2173_CR1","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.4049\/jimmunol.140.7.2330","volume":"140","author":"C Brashem-Stein","year":"1988","unstructured":"Brashem-Stein C, Nugent D, Bernstein ID. Characterization of an antigen expressed on activated human T cells and platelets. J Immunol. 1988;140:2330\u20133.","journal-title":"J Immunol"},{"key":"2173_CR2","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V77.1.84.84","volume":"77","author":"DR Sutherland","year":"1991","unstructured":"Sutherland DR, Yeo E, Ryan A, Mills GB, Bailey D, Baker MA. Identification of a cell-surface antigen associated with activated T lymphoblasts and activated platelets. Blood. 1991;77:84\u201393.","journal-title":"Blood"},{"key":"2173_CR3","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1182\/blood.V99.5.1683","volume":"99","author":"M Lin","year":"2002","unstructured":"Lin M, Sutherland DR, Horsfall W, Totty N, Yeo E, Nayar R, et al. Cell surface antigen CD109 is a novel member of the \u03b12 macroglobulin\/C3, C4, C5 family of thioester-containing proteins. Blood. 2002;99:1683\u201391.","journal-title":"Blood"},{"key":"2173_CR4","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1006\/cimm.1994.1181","volume":"156","author":"A Haregewoin","year":"1994","unstructured":"Haregewoin A, Solomon K, Hom RC, Soman G, Bergelson JM, Bhan AK, et al. Cellular expression of a GPI-linked T cell activation protein. Cell Immunol. 1994;156:357\u201370.","journal-title":"Cell Immunol"},{"key":"2173_CR5","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/S0301-472X(99)00071-5","volume":"27","author":"LJ Murray","year":"1999","unstructured":"Murray LJ, Bruno E, Uchida N, Hoffman R, Nayar R, Yeo EL, et al. CD109 is expressed on a subpopulation of CD34+ cells enriched in hematopoietic stem and progenitor cells. Exp Hematol. 1999;27:1282\u201394.","journal-title":"Exp Hematol"},{"key":"2173_CR6","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood.V86.7.2807.2807","volume":"86","author":"JW Smith","year":"1995","unstructured":"Smith JW, Hayward CP, Horsewood P, Warkentin TE, Denommme GA, Kelton J. Characterization and localization of the GOVa\/b alloantigens to the glycosylphosphatidylinositol-anchored protein CDwl09 on human platelets. Blood. 1995;86:2807\u201314.","journal-title":"Blood"},{"key":"2173_CR7","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.1038\/sj.onc.1207418","volume":"23","author":"M Hashimoto","year":"2004","unstructured":"Hashimoto M, Ichihara M, Watanabe T, Kawai K, Koshikawa K, Yuasa N, et al. Expression of CD109 in human cancer. Oncogene. 2004;23:3716\u201320.","journal-title":"Oncogene"},{"key":"2173_CR8","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/j.1440-1827.2007.02168.x","volume":"57","author":"T Sato","year":"2007","unstructured":"Sato T, Murakumo Y, Hagiwara S, Jijiwa M, Suzuki C, Yatabe Y, et al. High-level expression of CD109 is frequently detected in lung squamous cell carcinomas. Pathol Int. 2007;57:719\u201324.","journal-title":"Pathol Int"},{"key":"2173_CR9","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1440-1827.2008.02225.x","volume":"58","author":"M Hasegawa","year":"2008","unstructured":"Hasegawa M, Moritani S, Murakumo Y, Sato T, Hagiwara S, Suzuki C, et al. CD109 expression in basal-like breast carcinoma. Pathol Int. 2008;58:288\u201394.","journal-title":"Pathol Int"},{"key":"2173_CR10","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1111\/j.1349-7006.2008.00731.x","volume":"99","author":"S Hagiwara","year":"2008","unstructured":"Hagiwara S, Murakumo Y, Sato T, Shigetomi T, Mitsudo K, Tohnai I, et al. Up-regulation of CD109 expression is associated with carcinogenesis of the squamous epithelium of the oral cavity. Cancer Sci. 2008;99:1916\u201323.","journal-title":"Cancer Sci"},{"key":"2173_CR11","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1440-1827.2010.02592.x","volume":"60","author":"M Hagikura","year":"2010","unstructured":"Hagikura M, Murakumo Y, Hasegawa M, Jijiwa M, Hagiwara S, Mii S, et al. Correlation of pathological grade and tumor stage of urothelial carcinomas with CD109 expression. Pathol Int. 2010;60:735\u201343.","journal-title":"Pathol Int"},{"key":"2173_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jdermsci.2009.11.004","volume":"57","author":"Y Ohshima","year":"2010","unstructured":"Ohshima Y, Yajima I, Kumasaka MY, Yanagishita T, Watanabe D, Takahashi M, et al. CD109 expression levels in malignant melanoma. J Dermatol Sci. 2010;57:140\u20132.","journal-title":"J Dermatol Sci"},{"key":"2173_CR13","doi-asserted-by":"publisher","first-page":"e84187","DOI":"10.1371\/journal.pone.0084187","volume":"8","author":"M Emori","year":"2013","unstructured":"Emori M, Tsukahara T, Murase M, Kano M, Murata K, Takahashi A, et al. High expression of CD109 antigen regulates the phenotype of cancer stem-like cells\/cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One. 2013;8:e84187.","journal-title":"PLoS One"},{"key":"2173_CR14","doi-asserted-by":"publisher","first-page":"12083","DOI":"10.1007\/s13277-014-2509-5","volume":"35","author":"J Tao","year":"2014","unstructured":"Tao J, Li H, Li Q, Yang Y. CD109 is a potential target for triple-negative breast cancer. Tumour Biol. 2014;35:12083\u201390.","journal-title":"Tumour Biol"},{"key":"2173_CR15","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1111\/1346-8138.12620","volume":"41","author":"F Dong","year":"2014","unstructured":"Dong F, Wang Y, Li L, Wang Y, Liu X, Liu J. CD109 expression is increased in cutaneous squamous cell carcinoma. J Dermatol. 2014;41:947\u20139.","journal-title":"J Dermatol"},{"key":"2173_CR16","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1096\/fj.05-5229fje","volume":"20","author":"KW Finnson","year":"2006","unstructured":"Finnson KW, Tam BY, Liu K, Marcoux A, Lepage P, Roy S, et al. Identification of CD109 as part of the TGF-\u03b2 receptor system in human keratinocytes. Faseb J. 2006;20:1525\u20137.","journal-title":"Faseb J"},{"key":"2173_CR17","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/onc.2009.506","volume":"29","author":"S Hagiwara","year":"2010","unstructured":"Hagiwara S, Murakumo Y, Mii S, Shigetomi T, Yamamoto N, Furue H, et al. Processing of CD109 by furin and its role in the regulation of TGF-\u03b2 signaling. Oncogene. 2010;29:2181\u201391.","journal-title":"Oncogene"},{"key":"2173_CR18","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.01.028","volume":"1813","author":"AA Bizet","year":"2011","unstructured":"Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finnson KW, et al. The TGF-\u03b2 co-receptor, CD109, promotes internalization and degradation of TGF-\u03b2 receptors. Biochim Biophys Acta. 2011;1813:742\u201353.","journal-title":"Biochim Biophys Acta"},{"key":"2173_CR19","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/jcb.23349","volume":"113","author":"AA Bizet","year":"2012","unstructured":"Bizet AA, Tran-Khanh N, Saksena A, Liu K, Buschmann MD, Philip A. CD109-mediated degradation of TGF-\u03b2 receptors and inhibition of TGF-\u03b2 responses involve regulation of SMAD7 and Smurf2 localization and function. J Cell Biochem. 2012;113:238\u201346.","journal-title":"J Cell Biochem"},{"key":"2173_CR20","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/j.1600-0625.2011.01288.x","volume":"20","author":"IV Litvinov","year":"2011","unstructured":"Litvinov IV, Bizet AA, Binamer Y, Jones DA, Sasseville D, Philip A. CD109 release from the cell surface in human keratinocytes regulates TGF-\u03b2 receptor expression, TGF-\u03b2 signaling and STAT3 activation: relevance to psoriasis. Exp Dermatol. 2011;20:627\u201332.","journal-title":"Exp Dermatol"},{"key":"2173_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.bbrc.2015.02.093","volume":"459","author":"JM Zhang","year":"2015","unstructured":"Zhang JM, Murakumo Y, Hagiwara S, Jiang P, Mii S, Kalyoncu E, et al. CD109 attenuates TGF-\u03b21 signaling and enhances EGF signaling in SK-MG-1 human glioblastoma cells. Biochem Biophys Res Commun. 2015;459:252\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"2173_CR22","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.bbrc.2015.12.063","volume":"469","author":"H Sakakura","year":"2016","unstructured":"Sakakura H, Mii S, Hagiwara S, Kato T, Yamamoto N, Hibi H, et al. CD109 is a component of exosome secreted from cultured cells. Biochem Biophys Res Commun. 2016;469:816\u201322.","journal-title":"Biochem Biophys Res Commun"},{"key":"2173_CR23","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1042\/BJ20141488","volume":"473","author":"C Li","year":"2016","unstructured":"Li C, Hancock MA, Sehgal P, Zhou S, Reinhardt DP, Philip A. Soluble CD109 binds TGF-\u03b2 and antagonizes TGF-\u03b2 signaling and responses. Biochem J. 2016;473:537\u201347.","journal-title":"Biochem J"},{"key":"2173_CR24","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European\u2013American classification of lymphoid neoplasms: a proposal from the international Lymphoma Study Group. Blood. 1994;84:1361\u201392.","journal-title":"Blood"},{"key":"2173_CR25","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.leu.2404449","volume":"21","author":"P Paepe De","year":"2007","unstructured":"De Paepe P, De Wolf-Peeters C. Diffuse large B-cell lymphoma: a heterogeneous group of non-Hodgkin lymphomas comprising several distinct clinicopathological entities. Leukemia. 2007;21:37\u201343.","journal-title":"Leukemia"},{"key":"2173_CR26","doi-asserted-by":"publisher","first-page":"6351","DOI":"10.1200\/JCO.2005.05.012","volume":"23","author":"IS Lossos","year":"2005","unstructured":"Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol. 2005;23:6351\u20137.","journal-title":"J Clin Oncol"},{"key":"2173_CR27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1200\/JCO.2001.19.2.389","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2001;19:389\u201397.","journal-title":"J Clin Oncol"},{"key":"2173_CR28","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342.","journal-title":"N Engl J Med"},{"key":"2173_CR29","doi-asserted-by":"publisher","first-page":"4117","DOI":"10.1200\/JCO.2005.09.131","volume":"23","author":"P Feugier","year":"2005","unstructured":"Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d\u2019Etude des Lymphomes de l\u2019Adulte. J Clin Oncol. 2005;23:4117\u201326.","journal-title":"J Clin Oncol"},{"key":"2173_CR30","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379\u201391.","journal-title":"Lancet Oncol"},{"key":"2173_CR31","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1182\/blood-2006-09-047068","volume":"109","author":"H Nyman","year":"2007","unstructured":"Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, et al. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood. 2007;109:4930\u20135.","journal-title":"Blood"},{"key":"2173_CR32","doi-asserted-by":"publisher","unstructured":"The International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394.","DOI":"10.1056\/NEJM199309303291402"},{"key":"2173_CR33","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhannabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857\u201361.","journal-title":"Blood"},{"key":"2173_CR34","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"2173_CR35","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fishear RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med. 2002;346:1937\u201347.","journal-title":"N Engl J Med"},{"key":"2173_CR36","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.clml.2014.05.002","volume":"14","author":"JA Read","year":"2014","unstructured":"Read JA, Koff JL, Nastoupil LJ, Williams JN, Cohen JB, Flowers CR. Evaluating cell-of origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms. Clin Lymphoma Myeloma Leuk. 2014;14:460\u20137.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2173_CR37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"2173_CR38","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.leukres.2011.12.012","volume":"36","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Bertran BE, Song MK, Ilic I, Leppa S, Nurmi H, et al. The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP. Leuk Res. 2012;36:413\u20137.","journal-title":"Leuk Res"},{"key":"2173_CR39","first-page":"1860","volume":"31","author":"PP Carbone","year":"1971","unstructured":"Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin\u2019s disease staging classification. Cancer Res. 1971;31:1860\u20131.","journal-title":"Cancer Res"},{"key":"2173_CR40","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/jso.23934","volume":"111","author":"M Emori","year":"2015","unstructured":"Emori M, Tsukahara T, Murata K, Sugita S, Sonoda T, Kaya M, et al. Prognostic impact of CD109 expression in myxofibrosarcoma. J Surg Oncol. 2015;111:975\u20139.","journal-title":"J Surg Oncol"},{"key":"2173_CR41","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nrc1926","volume":"6","author":"B Bierie","year":"2006","unstructured":"Bierie B, Moses HL. Tumour microenvironment: TGF\u03b2: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer. 2006;6:506\u201320.","journal-title":"Nat Rev Cancer"},{"key":"2173_CR42","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1006\/excr.1998.4096","volume":"242","author":"A Saltzman","year":"1998","unstructured":"Saltzman A, Munro R, Searfoss G, Franks C, Jaye M, Ivashchenko Y. Transforming growth factor-\u03b2-mediated apoptosis in the Ramos B-lymphoma cell line is accompanied by caspase activation and Bcl-XL downregulation. Exp Cell Res. 1998;242:244\u201354.","journal-title":"Exp Cell Res"},{"key":"2173_CR43","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1074\/jbc.M808080200","volume":"284","author":"LC Spender","year":"2009","unstructured":"Spender LC, Inman GJ. TGF-\u03b2 induces growth arrest in Burkett lymphoma cells via transcriptional repression of E2F-1. J Biol Chem. 2009;284:1435\u201342.","journal-title":"J Biol Chem"},{"key":"2173_CR44","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1038\/onc.2012.219","volume":"32","author":"KC Kawabata","year":"2013","unstructured":"Kawabata KC, Ehata S, Komuro A, Takeuchi K, Miyazono K. TGF-\u03b2-induced apoptosis of B-cell lymphoma Ramos cells through reduction of MS4A1\/CD20. Oncogene. 2013;32:2096\u2013106.","journal-title":"Oncogene"},{"key":"2173_CR45","doi-asserted-by":"publisher","first-page":"9903","DOI":"10.1007\/s13277-015-3700-z","volume":"36","author":"S Mao","year":"2015","unstructured":"Mao S, Yang W, Ai L, Li Z, Jin J. Transforming growth factor \u03b2 type II receptor as a marker in diffuse large B cell lymphoma. Tumour Biol. 2015;36:9903\u20138.","journal-title":"Tumour Biol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2173-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2173-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T13:32:06Z","timestamp":1692624726000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2173-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,28]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2173"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2173-1","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,28]]}}}